These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4382384)

  • 21. Experimental tumour immunology.
    Nagy I; Ats M; Koszoru M; Majorossy K
    Arch Ital Patol Clin Tumori; 1966; 9(1):81-7. PubMed ID: 5998090
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacological studies on bimolane (AT-1727), a new antineoplastic agent (author's transl)].
    Zhang TM; Chen ZY; Lin C
    Yao Xue Xue Bao; 1980 Oct; 15(10):577-83. PubMed ID: 7257778
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of stimulatory and inhibitory agents during experimental testing of the function of nonspecific defense mechanisms].
    Pfordte K; Ponsold W
    Z Gesamte Hyg; 1973 Feb; 19(2):103-5. PubMed ID: 4701317
    [No Abstract]   [Full Text] [Related]  

  • 24. [Interrelations of zymosan, properdin & tumors. III. Behavior of the properdin level in benzopyrene sarcoma-bearing rats treated with zymosan].
    FUMAROLA D; MODICA F
    Tumori; 1959; 45(1):46-53. PubMed ID: 13659609
    [No Abstract]   [Full Text] [Related]  

  • 25. [Fibrinolysis and factors of aspecific immunity. Preliminary note].
    Ferrauto A; Giuffrida G; Terranova R
    Boll Soc Ital Biol Sper; 1965 Dec; 41(24):1488-91. PubMed ID: 5878160
    [No Abstract]   [Full Text] [Related]  

  • 26. Elevation of properdin levels in mice following administration of bacterial lipopolysaccharides.
    LANDY M; PILLEMER L
    J Exp Med; 1956 Jun; 103(6):823-33. PubMed ID: 13319594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Studies on the properdin system in hemoblastosis].
    Reissmann G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1965; 83(1):1-9. PubMed ID: 4157878
    [No Abstract]   [Full Text] [Related]  

  • 28. [The influecing of specific and unspecific immunobiological reactions through cytostatics].
    Wilde J; Schabinski G
    Z Gesamte Exp Med Einschl Exp Chir; 1967; 144(3):250-7. PubMed ID: 4968516
    [No Abstract]   [Full Text] [Related]  

  • 29. The properdin system and immunity. III. The zymosan assay of properdin.
    PILLEMER L; BLUM L; LEPOW IH; WURZ L; TODD EW
    J Exp Med; 1956 Jan; 103(1):1-13. PubMed ID: 13278451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Enrichment and immunologic determination of properdin in serum].
    Tympner KD; Strauch L
    Monatsschr Kinderheilkd (1902); 1968 Jun; 116(6):394-7. PubMed ID: 5718330
    [No Abstract]   [Full Text] [Related]  

  • 31. [Relation between zymosan, properdin & tumors. I. Effect of zymosan on the development of benzpyrene-induced sarcomas].
    MODICA F
    Tumori; 1958; 44(6):538-48. PubMed ID: 13635872
    [No Abstract]   [Full Text] [Related]  

  • 32. [THE ROLE OF THE PROPERDIN SYSTEM IN NON-SPECIFIC IMMUNITY].
    HOSHINO A
    Nihon Naika Gakkai Zasshi; 1963 Dec; 52():1023-40. PubMed ID: 14158037
    [No Abstract]   [Full Text] [Related]  

  • 33. Growth of transplantable tumours in animals during combined treatment with cytostatics and yeast cell wall polysaccharide zymosan.
    Pfordte K; Ponsold W
    Neoplasma; 1971; 18(2):173-7. PubMed ID: 5577315
    [No Abstract]   [Full Text] [Related]  

  • 34. The properdin system and immunity. XI. Studies on the interaction of zymosan with the properdin system.
    BLUM L; PILLEMER L; LEPOW IH
    Z Immun exp ther; 1959; 118():313-28. PubMed ID: 13801695
    [No Abstract]   [Full Text] [Related]  

  • 35. [Comparison of 2 methods of assaying properdin: the turbidimetric-inulin method and the classic method of Pillemer].
    Eberhardt A; Jasser S
    Przegl Epidemiol; 1966; 20(4):423-6. PubMed ID: 5959782
    [No Abstract]   [Full Text] [Related]  

  • 36. [Mouse protection studies with zymosan vaccines and properdin sera. Contribution to unspecified immunity (resistance)].
    ZIMMERMANN G
    Acta Biol Med Ger; 1962; 9():412-27. PubMed ID: 14003718
    [No Abstract]   [Full Text] [Related]  

  • 37. [Experimental research on the antineoplastic activity of osaĭin].
    Shvarev IF; Tsetlin AL; Nikol'skaia BS; Nikonov GK
    Vopr Onkol; 1966; 12(3):64-6. PubMed ID: 5991963
    [No Abstract]   [Full Text] [Related]  

  • 38. [The effect of zymosan on the toxicity and activity of various antitumor preparations].
    Veksler IG
    Vopr Onkol; 1966; 12(8):80-6. PubMed ID: 4972211
    [No Abstract]   [Full Text] [Related]  

  • 39. [Nonspecific stimulus therapy and the properdin system].
    Reissmann G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1966; 85(2):125-31. PubMed ID: 4167542
    [No Abstract]   [Full Text] [Related]  

  • 40. [Validity and limitations in the determination of serum properdin by means of zymosan].
    ZANUSSI C; TASCHINI P; SELVA G; ORTOLANI C
    Boll Ist Sieroter Milan; 1958; 37(5-6):237-45. PubMed ID: 13560652
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.